OA04.03 A Randomized Phase 3 Study of Camrelizumab Plus Chemotherapy As 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
C. Zhou,G. Chen,Y. Huang,J. Zhou,L. Lin,J. Feng,Z. Wang,Y. Shu,J. Shi,Y. Hu,Q. Wang,Y. Cheng,J. Chen,X. Lin,Y. Wang,J. Huang,J. Cui,L. Cao,Y. Liu,Y. Zhang,Y. Pan,J. Zhao,L. Wang,J. Chang,Q. Chen,X. Ren,W. Zhang,Y. Fan,Z. He,J. Fang,K. Gu,X. Dong,F. Jin,H. Gao,G. An,C. Ding,X. Jiang,J. Xiong,X. Zhou,S. Hu,P. Lu,A. Liu,S. Guo,C. Zhu,B. Gao,Y. Chen,C. Hu,J. Zhang,H. Zhang,H. Zhao,Y. Zhou,Y. Tai
DOI: https://doi.org/10.1016/j.jtho.2019.08.425
IF: 20.121
2019-01-01
Journal of Thoracic Oncology
Abstract:Platinum-based chemotherapy remains 1st line therapy for advanced non-small cell lung cancer (NSCLC) without oncogenic drivers in China. Camrelizumab (SHR-1210, a potent anti‒PD-1 monoclonal antibody) has shown promising activity in multiple malignancies. Here, we report interim analysis results on efficacy and safety of camrelizumab plus carboplatin/pemetrexed as 1st line treatment in Chinese advanced/metastatic non-squamous NSCLC patients with negative oncogenic drivers. In this open-label, randomized, multicenter phase 3 study (SHR-1210-303), patients with advanced/metastatic, non-squamous NSCLC with negative EGFR or ALK were stratified by sex and smoking history (≥ 400/year versus ˂ 400/year) and were randomly assigned (1:1) to receive 4 to 6 cycles of carboplatin (AUC=5) plus pemetrexed (500 mg/m2) with or without camrelizumab (200 mg), followed by pemetrexed with or without camrelizumab as maintenance therapy up to disease progression or intolerable toxicity. Treatment was given every 3 weeks. Crossover to camrelizumab monotherapy was permitted for patients in the chemotherapy arm who had confirmed disease progression. The primary endpoint was PFS per blinded independent central review according to RECIST v1.1. Secondary endpoints included ORR, DCR, DoR and OS. Data of subgroup analysis will be reported. Clinical Trials.gov number: NCT03134872. Between May 12, 2017 and Jun 6, 2018, 419 patients were randomized, among whom 205 received camrelizumab plus chemotherapy and 207 received chemotherapy treatment. After a median follow-up of 11.9 months, median PFS was 11.3 months (95% CI 9.5‒not reached) in camrelizumab plus chemotherapy arm and 8.3 months (95% CI 6.0‒9.7) in chemotherapy arm (HR 0.61 [95% CI 0.46‒0.80], p=0.0002). ORR, DCR, DoR and OS with camrelizumab plus chemotherapy were superior to chemotherapy (Table 1). Grade 3/4 adverse events occurred in 66.8% of patients in camrelizumab plus chemotherapy arm and 51.2% of patients in chemotherapy arm. There were 5 treatment-related deaths in camrelizumab plus chemotherapy arm and 4 in chemotherapy arm.Table 1Responses per blinded independent central review and overall survival in the total study populationCamrelizumab plus chemotherapy (n=205)Chemotherapy alone (n=207)p-valueObjective response rate60.0% (53.0‒66.8)39.1% (32.4‒46.1)p<0.0001Disease control rate87.3% (82.0‒91.6)74.4% (67.9‒80.2)p=0.0009Duration of response (months)17.6 (11.6‒NR)9.9 (8.5‒13.8)p=0.0356Overall survival (months)NR (17.1‒NR)20.9 (14.2‒NR)p=0.0272Data are shown in % (95% CI) or median (95% CI). NR: not reached. Open table in a new tab Data are shown in % (95% CI) or median (95% CI). NR: not reached. First-line camrelizumab plus chemotherapy shows substantial clinical benefit in patients with advanced/metastatic non-squamous NSCLC with negative EGFR or ALK in terms of PFS, ORR, and OS and acceptable safety profiles. The combination should become novel standard 1st line therapy for this population.